Healthcare Industry News: schizophrenia
News Release - March 28, 2011
XTL Biopharmaceuticals to Acquire MinoGuard Ltd.MinoGuard, a Private Biotechnology Company Developing Drugs for Mental Health Diseases, With its Lead Compound, SAM-101 for the Treatment of schizophrenia;
MinoGuard Successfully Completed a 70 Patient Phase 2a Clinical Trial in schizophrenia - use of the Drug Indicated Improvement of the Positive Symptoms of the Disease as well as Decrease of its Negative Symptoms
HERZLIYA, Israel, March 28, 2011 -- (Healthcare Sales & Marketing Network) -- XTL announced on March 24, 2011, it entered into a term sheet to acquire the activity of MinoGuard Ltd. ("MinoGuard") by obtaining an exclusive license to use MinoGuard's entire technology in return for royalties on sales and milestone payments throughout the clinical development process. MinoGuard was founded in 2007 in order to commercialize combination therapies for treating psychotic diseases, focusing on schizophrenia. The transaction is subject, among other things, to due diligence studies, examination of the regulatory track for the continued development of the drug and the approval of the Company's board.
MinoGuard was founded by Mor research Applications Ltd., Clalit Health Services technology transfer office, on the basis of a discovery made by Prof. Yechiel Levkovitz and Dr. Shlomo Mendlovic, heads of departments at the Shalvata Mental Health Center.
SAM-101, MinoGuard's leading drug, is based on a combination of existing anti-psychotic drugs and a recognized medicinal compound.
MinoGuard has successfully completed a phase 2a prospective, randomized, double-blind, placebo-controlled, clinical trial conducted on about 70 schizophrenics. The trial's endpoints were met, proving that SAM-101 improves the positive symptoms of the disease as well as the patients' cognitive state, minimizes the negative symptoms (social parameters and patient cognition) and reduces side effects such as overweight among patients.
schizophrenia is a severe and chronic (psychotic) mental illness and one of the most common. It affects the majority of social and mental functions, mood, perception, thought and cognitive functions according to the United States National Institute of Mental Health approximately 1.1% of the adult population in the United States has schizophrenia. According to a research by Decision Resources, the schizophrenia treatment industry in 2009 amounted to approximately $ 5.6 billion.
David Grossman, XTL's CEO mentioned that "The acquisition of MinoGuard would be in line with the Company's strategy to focus on late-stage clinical development drugs and treatments with a known safety profile, which address large markets with clear unmet clinical needs". Grossman added "it is our intention to continue with our strategy to broaden our drug development pipeline".
About XTL Biopharmaceuticals, Ltd
XTL Biopharmaceuticals, Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products. The Company is focused on developing a drug for the treatment of multiple myeloma and Hepatitis C. The Company has a unique treatment for multiple myeloma cancer patients based on EPO, a genetically engineered version of a natural hormone produced by the kidneys. The drug has been approved for marketing by the FDA and has for many years been sold for billions of dollars across the world for the treatment of severe anemia. Additionally, the Company has an agreement with Presidio Pharmaceuticals, Inc., to develop a drug for the treatment of Hepatitis C based on the Company's DOS technology.
XTL is a public company traded on the Tel Aviv Stock Exchange (TASE:XTL.ta ) and its ADRs are quoted in the US on the Pink Sheets (Pink Sheets:XTLBY.pk ).
For further details, please contact:
XTL Investor Relations, Tel: +972-9-955-7080 or email: firstname.lastname@example.org
Source: XTL Biopharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.